Patents Examined by Ekaterina Poliakova-Georgantas
  • Patent number: 11952631
    Abstract: The present invention pertains to a method for the identification of genetic variants that are associated with the severity of an infectious disease. The invention further pertains to a set of genetic factors associated with the severity of Human respiratory syncytial virus (HRSV) infection, for example in human infants. The genetic polymorphisms identified according to the present invention are for use in the diagnostic of infectious diseases and patient stratification in order to avoid or reduce the occurrence of fatal events during infection or to elect the most appropriate therapeutic approach to treat the disease.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: April 9, 2024
    Assignees: MEDIZINISCHE HOCHSCHULE HANNOVER, TWINCORE ZENTRUM FÜR EXPERIMENTELLE UND KLINISCHE INFEKTIONSFORSCHUNG GMBH, TECHNISCHE UNIVERSITÄT DRESDEN
    Inventors: Daniel Todt, Sibylle Haid, Martin Wetzke, Gesine Hansen, Chris Lauber, Lars Kaderali, Thomas Pietschmann
  • Patent number: 11951178
    Abstract: A nanoparticle delivery system designed for sustained delivery of microRNA-150 (miR-150) to FLT3-overexpressing acute myeloid leukemia (AML) cells, the delivery system comprising poly(amidoamine) (PAMAM) dendrimers complexed with miR-150, wherein at least one dendrimer is surface-functionalized with a ligand specific for FLT3 receptor, and methods for treating AML characterized by FLT3-overexpression are provided.
    Type: Grant
    Filed: July 14, 2021
    Date of Patent: April 9, 2024
    Assignees: University of Cincinnati, University of Chicago, The Board of Trustees of the University of Illinois
    Inventors: Jianjun Chen, Seungpyo Hong, Xi Jiang, Zejuan Li
  • Patent number: 11952574
    Abstract: Oligonucleotides are provided herein that inhibit TMPRSS6 expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with hepcidin deficiency or suppression.
    Type: Grant
    Filed: June 23, 2023
    Date of Patent: April 9, 2024
    Assignees: Novo Nordisk A/S, Dicerna Pharmaceuticals, Inc.
    Inventors: Anna Linda Blois, Christina Marie Priest, Jihye Park, Henryk Dudek
  • Patent number: 11937604
    Abstract: A nucleotide sequence is shown in SEQ ID NO.1. The gene encodes mannosyltransferase I. The gene plays an important role in the normal reproductive development of the Nilaparvata lugens (Stål). Inhibition of the function of the gene may reduce the survival rate of the Nilaparvata lugens (Stål) and hinder embryonic development. With respect to reduction of the survival rate of the Nilaparvata lugens (Stål) and hindering of embryonic development, the present invention can reduce the harm of the Nilaparvata lugens (Stål) to rice by killing the Nilaparvata lugens (Stål). By using the characteristic that the nucleotide sequence of a highly conserved target gene has no homology with the nucleotide sequence of natural enemies of the Nilaparvata lugens (Stål), RNA interference is performed at a nucleic acid level, to avoid the harm to non-target organisms such as natural enemies, thereby realizing green control of the Nilaparvata lugens (Stål) while controlling pests.
    Type: Grant
    Filed: September 13, 2021
    Date of Patent: March 26, 2024
    Inventors: Yabin Li, Ronger Zheng, Yipeng Xu, Xiaoping Yu
  • Patent number: 11939582
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of sodium voltage-gated channel alpha subunit 2 (SCN2A) in a subject. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a sodium voltage gated channel alpha subunit 1 (SCN1A) related disease or disorder (e.g., Dravet syndrome) in a subject in need.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: March 26, 2024
    Assignee: RogCon, Inc.
    Inventor: Steven Petrou
  • Patent number: 11920132
    Abstract: Antisense oligonucleotides target the mutation in intron 26 of the CEP290 gene and reduce inclusion of the aberrant exon into the CEP290 mRNA. The oligonucleotides include no more than 3 consecutive guanosines, have no more than 60% guanosine nucleobases, include at most one CpG sequence, and/or do not have the potential to form a hairpin comprising 3 or more consecutive complementary base pairs.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: March 5, 2024
    Assignee: ProQR Therapeutics II B.V.
    Inventors: Patricia Coromoto Biasutto, Hee Lam Chan
  • Patent number: 11912996
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: March 30, 2022
    Date of Patent: February 27, 2024
    Assignee: DICERNA PHARMACEUTICALS, INC.
    Inventors: Bob Dale Brown, Henryk T. Dudek
  • Patent number: 11891604
    Abstract: The present invention relates to use of miR-18b for prevention, treatment, or diagnosis of muscle diseases or neuromuscular diseases, and specifically it was confirmed that, in a muscle disease by gene mutations model, gene mutations reduce miR-18b expression, cause dysregulation of miR-18b signaling pathways, and thus induce calcium signaling, cell differentiation inhibition, and apoptosis. Therefore, miR-18b of the present invention may be used as a target factor for diagnosing and treating muscle diseases caused by gene mutations such as ALS and DMD.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: February 6, 2024
    Assignee: CURAMYS CO., LTD.
    Inventors: Jung-Joon Sung, Ki Yoon Kim
  • Patent number: 11885804
    Abstract: The invention relates to the application of the ERH gene in the preparation of bladder cancer diagnosis and treatment products. The ERH gene is found to have a good correlation with bladder cancer. In addition, an RNA interference vector is constructed to perform cell function experiments to study the effect of ERH gene on the proliferation and clonality of bladder cancer cells. The present invention provides a research basis for clinical diagnosis and treatment of bladder cancer and has a good application prospect.
    Type: Grant
    Filed: November 15, 2021
    Date of Patent: January 30, 2024
    Assignee: XUZHOU CENTRAL HOSPITAL
    Inventors: Conghui Han, Qian Lv, Kun Pang, Lin Hao, Ying Liu
  • Patent number: 11873492
    Abstract: The invention provides a medication and a diagnostic kit for inhibiting metastasis and invasion of breast cancer, an shRNA molecule for silencing expression of human LINC01614 and applications thereof. The shRNAs obtained by the invention can interfere with the expression of LINC01614, thereby reducing the migration and invasion ability of tumor cells, inhibiting the expression of EMT proteins, and inhibiting tumor formation and lung metastasis in an animal model in vivo. The invention provides a new solution for targeted therapy of breast cancer. Therefore, the kit for diagnosing metastasis and invasion of breast cancer and the medication for treating metastasis and invasion of breast cancer are developed. The invention provides a new way and strategy for diagnosing and treating metastasis and invasion of breast cancer.
    Type: Grant
    Filed: June 29, 2022
    Date of Patent: January 16, 2024
    Assignee: Zhejiang Chinese Medical University
    Inventors: Fangfang Tao, Zhiqian Zhang, Wenhong Liu, Ye Xu, Qingling Liu, Junfeng Li
  • Patent number: 11873495
    Abstract: Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of LRRK2 RNA in a cell or animal, and in certain instances reducing the amount of LRRK2 protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such symptoms and hallmarks include ataxia, neuropathy, and aggregate formation. Such neurodegenerative diseases include Parkinson's disease.
    Type: Grant
    Filed: April 4, 2022
    Date of Patent: January 16, 2024
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Tracy A. Cole, Susan M. Freier
  • Patent number: 11866700
    Abstract: Aspects of the invention relate to antisense oligonucleotides directed to the interleukin 17 receptor (IL-17R), and other targets. Spherical nucleic acid formulations or compositions of antisense oligonucleotides and related methods of treatment are also provided.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: January 9, 2024
    Assignee: Exicure Operating Company
    Inventors: Richard Kang, Scott Mix, Ekambar Kandimalla
  • Patent number: 11851658
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: June 9, 2022
    Date of Patent: December 26, 2023
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob Dale Brown, Henryk T. Dudek
  • Patent number: 11845938
    Abstract: Provided are aptamer compositions and their use for treating cancer.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: December 19, 2023
    Assignees: CITY OF HOPE, APTERNA LIMITED
    Inventors: John J. Rossi, Sorah Yoon, Nagy Habib
  • Patent number: 11839624
    Abstract: The present disclosure includes cationic carrier units comprising (i) a water soluble polymer, (ii) a positively charged carrier, and (iii) an adjuvant moiety, wherein when the cationic carrier unit is mixed with an anionic payload (e.g., an antisense oligonucleotide) that electrostatically interacts with the cationic carrier unit, the resulting composition self-organizes into a micelle encapsulating the anionic payload in its core. The cationic carrier units can also comprise a tissue specific targeting moiety, which would be displayed on the surface of the micelle. The disclosure also includes micelles comprising the cationic carrier units of the disclosure, methods of manufacture of cationic carrier units and micelles, pharmaceutical compositions comprising the micelles, and also methods of treating diseases or conditions comprising administering the micelles to a subject in need thereof.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: December 12, 2023
    Assignee: BIORCHESTRA CO., LTD.
    Inventors: Jin-Hyeob Ryu, Yu Na Lim, Hyun Su Min, Han Seok Koh, Dae Hoon Kim, Hyun-Jeong Cho
  • Patent number: 11834659
    Abstract: The present disclosure, at least in part, relates to an engineered RNA (e.g., microRNA and sgRNA), in the absence of an input signal, that is engineered to have a large enough energy gap between the formations of a first secondary structure, which is unrecognizable by an actuator, and a second secondary structure, which is recognizable by an actuator (e.g., Drosha and Cas protein).
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: December 5, 2023
    Assignee: Massachusetts Institute of Technology
    Inventors: Ron Weiss, Giulio Alighieri
  • Patent number: 11833168
    Abstract: Provided are compounds, methods, and pharmaceutical compositions for increasing the amount or activity of STMN2 RNA in a cell or animal, and in certain embodiments increasing the amount of STMN2 protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom of a neurodegenerative disease. Such symptoms include ataxia, neuropathy, synaptic dysfunction, deficits in cognition, and decreased longevity. Such neurodegenerative diseases include amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), and dementia with Lewy bodies (DLB).
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: December 5, 2023
    Assignees: Ionis Pharmaceuticals, Inc., Ludwig Institute For Cancer Research
    Inventors: Huynh-Hoa Bui, Don W. Cleveland, Ze'ev Melamed
  • Patent number: 11834661
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the AGT gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an AGT gene and to methods of preventing and treating an AGT-associated disorder, e.g., high blood pressure.
    Type: Grant
    Filed: April 7, 2021
    Date of Patent: December 5, 2023
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Donald Foster, Gregory Hinkle, Mark K. Schlegel
  • Patent number: 11827885
    Abstract: Compositions, methods and kits are provided that include an inhibitory oligonucleotide RNase inhibitor capable of inhibiting one or more types of RNase that coexist with biological samples or are introduced in the laboratory, thereby protecting RNA in the sample from degradation. More than one type of oligonucleotide RNase inhibitor may be combined in a mixture to inhibit a plurality of different RNases. Single oligonucleotides were identified to have inhibitory activity for a plurality of different RNases. The RNase oligonucleotide inhibitor may be immobilized on beads or other surface. It may be stored in a lyophilized form or in solution.
    Type: Grant
    Filed: March 19, 2021
    Date of Patent: November 28, 2023
    Assignee: New England Biolabs, Inc.
    Inventors: Nathan Tanner, Jennifer Ong, Esta Slayton, Lisa Maduzia, Salvatore V. Russello
  • Patent number: 11793828
    Abstract: The invention relates to inhibitors of microRNAs 19a and 19b and their use for treating or preventing conditions or diseases which are associated with bone loss, in particular osteoporosis and osteogenesis imperfect (OI). The inhibitors are also useful for inducing an anabolic effect in bone, either alone or when administered in combination with parathyroid hormone or a recombinant fragment thereof. The invention further relates to inhibitors of microRNAs 19a and 19b and their use for treating or preventing conditions or diseases which are associated with reduced muscle function, in particular muscle degeneration and muscle atrophy. The inhibitors are also useful for stabilizing and/or strengthening muscle function. In addition, inhibitors of microRNAs 19a and 19b can be used for treating or preventing cancer-related bone destruction or bone metastasis.
    Type: Grant
    Filed: May 14, 2021
    Date of Patent: October 24, 2023
    Assignee: UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF
    Inventors: Eric Hesse, Hanna Taipaleenmäki, Hiroaki Saito